Advertisement

Mucosal Barrier Defects: What Have We Learned from Atopic Dermatitis, Asthma, and Allergic Rhinitis?

  • Prestina Smith
  • Michael Koval
  • Joshua M. LevyEmail author
Otolaryngic Allergy (SK Wise and C Damask, Section Editors)
  • 9 Downloads
Part of the following topical collections:
  1. Otolaryngic Allergy

Abstract

Purpose of the Review

This review covers recent findings describing roles for tight junction proteins in the mucosal barrier and their dysfunction in atopic diseases.

Recent Findings

Mucosal barrier dysfunction is commonly associated with chronic inflammation. Changes in tight junction protein expression and localization can be indicators of disease progression in allergic rhinitis. In addition, alterations in tight junctions may have a role in the initial onset of asthma. Lastly, polymorphisms in tight junction genes can be early predictors for atopic dermatitis risk and severity.

Summary

Tight junctions play a vital role in maintenance of the epithelial barrier and are frequently disrupted in chronic inflammatory disease. Future study is warranted to evaluate novel targeted therapeutics that promote barrier function in the treatment of atopic disease.

Keywords

Tight junction Allergic rhinitis Atopic dermatitis Asthma Claudin Barrier function 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Emory University Institutional Review Board (IRB00102406) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    France MM, Turner JR. The mucosal barrier at a glance. J Cell Sci. 2017;130(2):307–14.  https://doi.org/10.1242/jcs.193482.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol. 2007;120(6):1279–84.  https://doi.org/10.1016/j.jaci.2007.08.046.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zihni CM, C, Matter K, Balda M. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17.  https://doi.org/10.1038/nrm.2016.80.CrossRefGoogle Scholar
  4. 4.
    Van Itallie CMAJ. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol. 2014;36:157–65.  https://doi.org/10.1016/j.semcdb.2014.08.011.CrossRefPubMedGoogle Scholar
  5. 5.
    Citi S. The mechanobiology of tight junctions. Biophys Rev. 2019;11(5):783–93.  https://doi.org/10.1007/s12551-019-00582-7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schlingmann B, Molina SA, Koval M. Claudins: gatekeepers of lung epithelial function. Semin Cell Dev Biol. 2015;42:47–57.  https://doi.org/10.1016/j.semcdb.2015.04.009.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kojima T, Go M, Takano K, Kurose M, Ohkuni T, Koizumi J, et al. Regulation of tight junctions in upper airway epithelium. Biomed Res Int. 2013;2013:947072.  https://doi.org/10.1155/2013/947072.CrossRefPubMedGoogle Scholar
  8. 8.
    • Fukuoka A, Yoshimoto T. Barrier dysfunction in the nasal allergy. Allergol Int. 2018;67(1):18–23.  https://doi.org/10.1016/j.alit.2017.10.006. A review that describes the relationship between TJ disruption and allergic diseases. CrossRefPubMedGoogle Scholar
  9. 9.
    Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev. 2005;57(6):883–917.  https://doi.org/10.1016/j.addr.2005.01.009.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Steelant B, Seys SF, Boeckxstaens G, Akdis CA, Ceuppens JL, Hellings PW. Restoring airway epithelial barrier dysfunction: a new therapeutic challenge in allergic airway disease. Rhinology. 2016;54(3):195–205.  https://doi.org/10.4193/Rhin15.376. A review highlighting the link between epithelial barrier dysfunction and allergic diseases. In addition to airway diseases, this review describes the role of TJs in other chronic inflammatory conditions such as AD, Chron’s disease and ulcerative colitis. CrossRefPubMedGoogle Scholar
  11. 11.
    •• Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352.  https://doi.org/10.1002/alr.22073. Comprehensive review of allergic rhinitis including pathophysiology and patient management. CrossRefPubMedGoogle Scholar
  12. 12.
    London NR Jr, Ramanathan M Jr. The role of the sinonasal epithelium in allergic rhinitis. Otolaryngol Clin N Am. 2017;50(6):1043–50.  https://doi.org/10.1016/j.otc.2017.08.002.CrossRefGoogle Scholar
  13. 13.
    •• Steelant B, Seys SF, Van Gerven L, Van Woensel M, Farre R, Wawrzyniak P, et al. Histamine and T helper cytokine-driven epithelial barrier dysfunction in allergic rhinitis. J Allergy Clin Immunol. 2018;141(3):951–63 e8.  https://doi.org/10.1016/j.jaci.2017.08.039. This study identifies allergic inflammatory mediators driving epithelial barrier dysfunction in AR. In addition, this study describes the epithelial barrier and TJ proteins in AR patient samples. CrossRefPubMedGoogle Scholar
  14. 14.
    • Steelant B, Farre R, Wawrzyniak P, Belmans J, Dekimpe E, Vanheel H, et al. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol. 2016;137(4):1043–53 e5.  https://doi.org/10.1016/j.jaci.2015.10.050. This study describes nasal epithelial barrier dysfunction and TJ protein disruption in HDM-inducted AR patient samples. CrossRefPubMedGoogle Scholar
  15. 15.
    Henriquez OA, Den Beste K, Hoddeson EK, Parkos CA, Nusrat A, Wise SK. House dust mite allergen Der p 1 effects on sinonasal epithelial tight junctions. Int Forum Allergy Rhinol. 2013;3(8):630–5.  https://doi.org/10.1002/alr.21168.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gon Y, Hashimoto S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma. Allergol Int. 2018;67(1):12–7.  https://doi.org/10.1016/j.alit.2017.08.011.CrossRefPubMedGoogle Scholar
  17. 17.
    Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol. 2011;128(3):549–56 e1–12.  https://doi.org/10.1016/j.jaci.2011.05.038.CrossRefPubMedGoogle Scholar
  18. 18.
    de Boer WI, Sharma HS, Baelemans SM, Hoogsteden HC, Lambrecht BN, Braunstahl GJ. Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation. Can J Physiol Pharmacol. 2008;86(3):105–12.  https://doi.org/10.1139/y08-004.CrossRefPubMedGoogle Scholar
  19. 19.
    •• Tan HT, Hagner S, Ruchti F, Radzikowska U, Tan G, Altunbulakli C, et al. Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice. Allergy. 2019;74(2):294–307.  https://doi.org/10.1111/all.13619. This study describes the differential expression of TJ proteins and inflammatory mediators in multiple murine models of house dust mite- induced asthma. CrossRefPubMedGoogle Scholar
  20. 20.
    • Sweerus K, Lachowicz-Scroggins M, Gordon E, LaFemina M, Huang X, Parikh M, et al. Claudin-18 deficiency is associated with airway epithelial barrier dysfunction and asthma, J Allergy Clin Immunol. 2017;139(1):72–81.  https://doi.org/10.1016/j.jaci.2016.02.035. e1 This study identifies decreased claudin-18 levels in human airway cells from patients with asthma. In addition, loss of claudin-18 led to barrier dysfunction in 16HBE cells and in mice. CrossRefGoogle Scholar
  21. 21.
    Rerknimitr P, Otsuka A, Nakashima C, Kabashima K. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen. 2017;37:14.  https://doi.org/10.1186/s41232-017-0044-7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    • Egawa G. Pathomechanism of 'skin-originated' allergic diseases. Immunol Med. 2018;41(4):170–6.  https://doi.org/10.1080/25785826.2018.1540257. This review describes the structure of the skin barrier and the role of TJs in the skin. In addition, the review covers recent findings implicating claudin-1 in AD. CrossRefPubMedGoogle Scholar
  23. 23.
    Agrawal R, Woodfolk JA. Skin barrier defects in atopic dermatitis. Curr Allergy Asthma Rep. 2014;14(5):433.  https://doi.org/10.1007/s11882-014-0433-9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773–86 e1–7.  https://doi.org/10.1016/j.jaci.2010.10.018.CrossRefPubMedGoogle Scholar
  25. 25.
    •• Asad S, Winge MC, Wahlgren CF, Bilcha KD, Nordenskjold M, Taylan F, et al. The tight junction gene Claudin-1 is associated with atopic dermatitis among Ethiopians. J Eur Acad Dermatol Venereol. 2016;30(11):1939–41.  https://doi.org/10.1111/jdv.13806. This study characterizesCLDN1polymorphisms as indicators of AD susceptibility in the Ethiopian population. CrossRefPubMedGoogle Scholar
  26. 26.
    • Yuki T, Tobiishi M, Kusaka-Kikushima A, Ota Y, Tokura Y. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One. 2016;11(9):e0161759.  https://doi.org/10.1371/journal.pone.0161759. This study finds TJ alterations and barrier dysfunction in skin biopsies from patients with AD. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    •• Steelant B, Wawrzyniak P, Martens K, Jonckheere AC, Pugin B, Schrijvers R, et al. Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis. J Allergy Clin Immunol. 2019.  https://doi.org/10.1016/j.jaci.2019.04.027. This study identifies increased HDAC activity as a mechanism contributing to epithelial barrier dysfunction. This study also identifies a HDAC inhibitor as a promising novel therapeutic for inflammatory airway diseases. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Prestina Smith
    • 1
  • Michael Koval
    • 1
    • 2
  • Joshua M. Levy
    • 3
    Email author
  1. 1.Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of MedicineEmory UniversityAtlantaUSA
  2. 2.Department of Cell BiologyEmory UniversityAtlantaUSA
  3. 3.Department of Otolaryngology- Head and Neck SurgeryEmory University School of MedicineAtlantaUSA

Personalised recommendations